文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

褪黑素受体激动剂雷美替胺对ICU停留时间的影响:单中心随机安慰剂对照试验

Effect of Administration of Ramelteon, a Melatonin Receptor Agonist, on the Duration of Stay in the ICU: A Single-Center Randomized Placebo-Controlled Trial.
PubMed 文献 · Crit Care Med · 2018-01-01
一句话结论在ICU可口服或鼻胃管给药的患者中,雷美替胺8 mg/d使谵妄发生率从46.5%降至24.4%,ICU停留时间有缩短趋势(4.56 d vs 5.86 d,校正后p=0.028)。

该单中心、三盲、随机安慰剂对照试验纳入88例ICU患者,随机分为雷美替胺组(45例,8 mg/d)和安慰剂组(43例,乳糖粉1 g/d),每日20:00给药至出ICU。主要终点ICU停留时间在雷美替胺组为4.56 d,安慰剂组为5.86 d,呈缩短趋势(校正前p=0.082,校正后p=0.028)。次要终点方面,雷美替胺组谵妄发生率显著降低(24.4% vs 46.5%,p=0.044),谵妄持续时间显著缩短(0.78 d vs 1.40 d,p=0.048)。非插管患者中,雷美替胺组每晚觉醒次数显著减少,无觉醒夜晚比例更高。

要点

  • 雷美替胺8 mg/d(20:00给药)使ICU谵妄发生率从46.5%降至24.4%(p=0.044)。
  • 雷美替胺组谵妄持续时间0.78 d,安慰剂组1.40 d(p=0.048)。
  • ICU停留时间雷美替胺组4.56 d vs 安慰剂组5.86 d,校正前p=0.082、校正后p=0.028,呈缩短趋势。
  • 非插管患者中雷美替胺组每晚觉醒次数显著减少,无觉醒夜晚比例更高。
  • 纳入标准为入ICU 48小时内可口服或鼻胃管给药的患者。

适用人群与场景

  • ICU患者,且在入ICU后48小时内可口服或经鼻胃管给药。

处置流程与药物剂量

  • 雷美替胺组:雷美替胺8 mg/d,每日20:00给药,至转出ICU。
  • 安慰剂组:乳糖粉1 g/d,每日20:00给药,至转出ICU。

研究设计与关键结果

  • 研究类型:单中心、三盲、随机安慰剂对照试验;样本量88例,随机分为雷美替胺组45例和安慰剂组43例。
  • 主要终点:ICU停留时间雷美替胺组4.56 d vs 安慰剂组5.86 d,呈缩短趋势(校正前p=0.082,校正后p=0.028)。
  • 关键次要终点:谵妄发生率雷美替胺组24.4% vs 安慰剂组46.5%(p=0.044);谵妄持续时间雷美替胺组0.78 d vs 安慰剂组1.40 d(p=0.048)。
  • 非插管患者中,雷美替胺组每晚觉醒次数显著少于安慰剂组,无觉醒夜晚比例显著高于安慰剂组。

证据类型、等级与局限

  • 证据类型:单中心、三盲、随机安慰剂对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于入ICU 48小时内可口服或鼻胃管给药的ICU患者,作者认为雷美替胺可能缩短ICU停留时间,并显著降低谵妄发生率和缩短谵妄持续时间。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Occurrence of delirium in the ICU is associated with a longer stay in the ICU. To examine whether the use of ramelteon, a melatonin agonist, can prevent delirium and shorten the duration of ICU stay of critically ill patients.

DESIGN: A single-center, triple-blinded, randomized placebo-controlled trial.

SETTING: ICU of an academic hospital.

PATIENTS: Eligible patients were ICU patients who could take medicines orally or through a nasogastric tube during the first 48 hours of admission.

INTERVENTIONS: The intervention group received ramelteon (8 mg/d), and the control group received placebo (1 g/d of lactose powder) at 20:00 hours every day until discharge from the ICU.

MEASUREMENTS AND MAIN RESULTS: A total of 88 subjects were randomized to the ramelteon group (45 subjects) or the placebo group (43 subjects). As the primary endpoint, there was a trend toward decrease in the duration of ICU stay (4.56 d) in the ramelteon group compared with the placebo group (5.86 d) (p = 0.082 and p = 0.028 before and after adjustments). As the secondary endpoints, statistically significant decreases in the occurrence rate (24.4% vs 46.5%; p = 0.044) and duration (0.78 vs 1.40 d; p = 0.048) of delirium were observed in the ramelteon group. The nonintubated patients of the ramelteon group showed statistically significantly fewer awakenings per night and a higher proportion of nights without awakenings.

CONCLUSIONS: Ramelteon tended to decrease the duration of ICU stay as well as decreased the occurrence rate and duration of delirium statistically significantly.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Nishikimi M, Numaguchi A, Takahashi K, et al. Effect of Administration of Ramelteon, a Melatonin Receptor Agonist, on the Duration of Stay in the ICU: A Single-Center Randomized Placebo-Controlled Trial. Crit Care Med. 2018. PMID: 29595562. doi:10.1097/CCM.0000000000003132

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。